140 related articles for article (PubMed ID: 3500659)
1. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma.
Pitchenik AE; Guffee J; Stein-Streilein J
Am Rev Respir Dis; 1987 Dec; 136(6):1327-32. PubMed ID: 3500659
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous lymphokine activated killer (LAK) activity in bronchoalveolar lavage cells from patients with bronchogenic carcinoma.
Stein-Streilein J; Guffee J; Ramos M; Pitchenik AE
Reg Immunol; 1989; 2(6):370-5. PubMed ID: 2485685
[TBL] [Abstract][Full Text] [Related]
3. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.
LeFever AV; Funahashi A
Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cell activity in lung cancer.
LeFever A; Funahashi A
Chest; 1991 Feb; 99(2):292-7. PubMed ID: 1989785
[TBL] [Abstract][Full Text] [Related]
5. Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2.
Robinson BW
Am Rev Respir Dis; 1989 Apr; 139(4):897-901. PubMed ID: 2784645
[TBL] [Abstract][Full Text] [Related]
6. Regional and systemic CD4 and CD8 subsets in bronchogenic carcinoma.
Liss HP; Baumann MA; Paul CC; Payne CB
Neth J Med; 1991 Dec; 39(5-6):333-7. PubMed ID: 1687075
[TBL] [Abstract][Full Text] [Related]
7. Natural killer activity is present in rat lung lavage and inhibited by lidocaine.
Renzi PM; Ginns LC
Immunopharmacol Immunotoxicol; 1990; 12(3):389-415. PubMed ID: 2266229
[TBL] [Abstract][Full Text] [Related]
8. Bronchoalveolar T-lymphocytes and subsets in pulmonary tuberculosis and bronchogenic carcinoma.
Pushpakom R; Pattanapanyasat K; Bovornkitti S
J Med Assoc Thai; 1990 Jan; 73(1):1-11. PubMed ID: 2345320
[TBL] [Abstract][Full Text] [Related]
9. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma.
Dunlap NE; Lane VG; Cloud GA; Tilden AB
Cancer; 1990 Oct; 66(7):1499-504. PubMed ID: 1698527
[TBL] [Abstract][Full Text] [Related]
10. [Study of pulmonary T cell subsets and killer activity in lung cancer].
Zhang DX
Zhonghua Jie He He Hu Xi Za Zhi; 1990 Apr; 13(2):78-81, 126. PubMed ID: 1975773
[TBL] [Abstract][Full Text] [Related]
11. A study of monokine release and natural killer activity in the bronchoalveolar lavage of subjects with farmer's lung.
Denis M; Bedard M; Laviolette M; Cormier Y
Am Rev Respir Dis; 1993 Apr; 147(4):934-9. PubMed ID: 8466130
[TBL] [Abstract][Full Text] [Related]
12. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells.
Robinson BW; Morstyn G
Cell Immunol; 1987 May; 106(2):215-22. PubMed ID: 3494538
[TBL] [Abstract][Full Text] [Related]
13. Exogenous interleukin 2 regulates interleukin 6 and nitric oxide but not interferon gamma and tumor necrosis factor alpha production in bronchoalveolar leukocytes from patients with small cell lung cancer.
Cembrzyńska-Nowak M; Bieńkowska M; Szklarz E
Arch Immunol Ther Exp (Warsz); 1998; 46(6):367-74. PubMed ID: 9883316
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of interleukin-2 on natural killer activity in lung cancer patients.
Ito M; Suzuki H; Yamashita N; Sugiyama E; Maruyama M; Sato M; Iwata M; Yano S
Anticancer Res; 1984; 4(6):375-8. PubMed ID: 6097158
[TBL] [Abstract][Full Text] [Related]
15. [Immunologic evaluation in patients with lung cancer with special regard to peripheral blood natural killer cell activity and interleukin-2 productivity].
Matsuse T; Fukuchi Y; Nagase T; Suruda T; Yamaoka M; Ishida K; Harada N; Toba K; Orimo H
Nihon Ronen Igakkai Zasshi; 1989 Sep; 26(5):475-80. PubMed ID: 2515327
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte subsets in bronchoalveolar lavage fluid and in circulating blood in epidermoid bronchogenic carcinoma.
Piazza G; Marchi E; Scaglione F; Montoli CC; Losi S; Scarpazza G
Respiration; 1990; 57(1):28-36. PubMed ID: 2359893
[TBL] [Abstract][Full Text] [Related]
17. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2, interferon-gamma and natural killer cell activity in bronchoalveolar lavage fluid from marrow transplant recipients with cytomegalovirus pneumonia.
Slavin M; Dobbs S; Crawford S; Bowden R
Bone Marrow Transplant; 1993 Feb; 11(2):113-8. PubMed ID: 8382095
[TBL] [Abstract][Full Text] [Related]
19. [Immunoglobulin and lysozyme levels in bronchoalveolar lavage fluid from patients with acute pneumonia in acute leukemia and bronchogenic carcinoma of the lung].
Ivashkin VT; Iakovlev VN; Borzenkov AS; Piasik MV
Klin Med (Mosk); 1990 Jun; 68(6):69-73. PubMed ID: 2214643
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
